Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 209-502-6 | CAS number: 583-39-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Justification for type of information:
- Data is from peer reviewed publication
Data source
Reference
- Reference Type:
- publication
- Title:
- Toxicity Study by Oral Administration To Rats.
- Author:
- Kawasaki et al.
- Year:
- 1 998
- Bibliographic source:
- The Journal of Toxicological Sciences
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: Refer below principle
- Principles of method if other than guideline:
- The present 28-day repeated dose oral toxicity study of test substance followed by 2-week recovery examination in Wistar rats was conducted to evaluate adverse effects and their reversibility
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Benzimidazole-2-thiol
- EC Number:
- 209-502-6
- EC Name:
- Benzimidazole-2-thiol
- Cas Number:
- 583-39-1
- Molecular formula:
- C7H6N2S
- IUPAC Name:
- 1H-benzimidazole-2-thiol
- Details on test material:
- SOURCE OF TEST MATERIAL
- Test Identity: 2-MBI (benzimidazole-2-thiol)
- Source and lot/batch No.of test material: Ouchi Shinko Chemical Ind., Ltd.(Osaka, Japan)
- Purity: >95%
- Substance type: Organic
- Physical state: Solid
- Molecular formula: C7H6N2S
- Molecular weight: 150.204 g/mol
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing:2-MBI was dissolved or suspended in corn oil and administered to rats by the i.g route using disposable gavage tube.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on species / strain selection:
- No data
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: SLC Co. (Shizuoka, Japan)
- Age at study initiation: 5 weeks old
- Weight at study initiation: male 92 g, females 80g
- Fasting period before study: 16 hours
- Housing: Rats were housed in plastic cages (5 rats/cage) using chip bedding.
- Diet (e.g. ad libitum): The basal pellet diet (F-2); ad libitum
- Water (e.g. ad libitum): Tap water; ad libitum
- Acclimation period: One week prior to the initiation of the study
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 24±1°C
- Humidity (%):55±5%
- Photoperiod (hrs dark / hrs light): 12 hr light/dark cycle
Administration / exposure
- Route of administration:
- oral: gavage
- Details on route of administration:
- No data
- Vehicle:
- corn oil
- Remarks:
- 2%
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: test chemical was dissolved or suspended in corn oil and administered to rats by the i.g route using disposable gavage tube.
DIET PREPARATION
- Rate of preparation of diet (frequency): No data
- Mixing appropriate amounts with (Type of food): No data
- Storage temperature of food: No data
VEHICLE
- Justification for use and choice of vehicle (if other than water): Corn oil
- Concentration in vehicle: 0, 2.0, 10.0 or 50.0 mg/Kg
- Amount of vehicle (if gavage): No data
- Lot/batch no. (if required): No data
- Purity: No data - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The stability of test substance in corn oil was examined by HPLC after extracting the test compound with methanol. The test chemical was confirmed to be stable for atleast 1 week at room temperature
- Duration of treatment / exposure:
- 28 days (14 days recovery period)
- Frequency of treatment:
- Daily for two consecutive weeks
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 other: mg/kg
- Remarks:
- Treatment period
- Dose / conc.:
- 2 other: mg/kg
- Remarks:
- Treatment period
- Dose / conc.:
- 10 other: mg/kg
- Remarks:
- Treatment period
- Dose / conc.:
- 50 other: mg/kg
- Remarks:
- Treatment group
- Dose / conc.:
- 0 other: mg/kg
- Remarks:
- Recovery period
- Dose / conc.:
- 50 other: mg/kg
- Remarks:
- Recovery period
- No. of animals per sex per dose:
- Total: 80
0 mg/Kg: 10 males and 10 females
2.0 mg/Kg: 10 males and 10 females
10.0 mg/Kg: 10 males and 10 females
50.0 mg/Kg: 10 males and 10 females - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: For the dose-determining study, male and female rats (5 rats/group) were orally administered 80 mg, 40, 20, 10 and 5 mg/kg of 2-MBI for a consecutive 2 weeks. Taking into account the observed reduction in body weight gain in groups receiving more than 40 mg/kg and the 2 weeks longer treatment period for the 28-day repeated oral toxicity study, doses of 0 (control, corn oil alone), 2, 10 and 50 mg/kg of 2-MBI were administered by gavage to groups of 10 male and 10 female rats for 28 consecutive days.
.
- Rationale for animal assignment (if not random): No data
- Rationale for selecting satellite groups: Yes
- Post-exposure recovery period in satellite groups: No data
- Section schedule rationale (if not random): No data - Positive control:
- No data
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: No data
- Cage side observations checked in table [No.?] were included. The animals were observed for mortality
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule:Clinical signs were monitored throughout the study.
BODY WEIGHT: Yes
- Time schedule for examinations: Three days prior to the initiation of the treatment. On the first day of treatment, and then twice weekly throughout the study.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes;once a week
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Not specified
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Not specified
- Time schedule for examinations: No data
OPHTHALMOSCOPIC EXAMINATION: Not specified
- Time schedule for examinations: No data
- Dose groups that were examined: No data
HAEMATOLOGY: Yes
- Anaesthetic used for blood collection: No data
- Animals fasted: No data
- How many animals: 5 animals/sex
- Parameters checked : Red blood cells (REC), hemoglobin (Hb), hematocrict (HCT), mean corpuscular volume (MCV), mean hemo-globin concentration (MHC), mean corpuscular homoglobin concentration (MCHC), platelets (PLT) and white blood cells {WBC), blood clotting time
CLINICAL CHEMISTRY: Yes
- Animals fasted: No data
- How many animals: 5 animals/sex
- Parameters checked : Total protein (TP), albumin (ALB), blood urea nitrogen (BUN), creatinine (CRN), glucose (GLC),non esterified fatty acid (NEFA), phospholipid (PL),triglyceride (TG), total cholesterol (T-CHO), free cholesterol (F-CHO), alkaline phosphatase (ALP), amylase (AMY), cholinesterase (CHE). aspartate aminotransferase (AST), alanine aminotransferase (ALT). gamma -glutamyl transpeptidase ( y -GTP), leucine aminopeptidase CLAP ), lactate dehydrogenase (LDH). calcium (Ca),magnesium (Mg2+), inorganic posphorus (Pi), sodium (Na+), potassium (K+). and chlorine (CI-) were analyzed. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
The weights of the brain, heart, lungs,liver, kidneys, spleen, adrenals, testes, ovaries, pituitary, thymus, submaxillary glands and thyroid glands of each animals were measured.
HISTOPATHOLOGY: Yes
The brain, heart, lungs, liver, kidneys, spleen, adrenals, testes, ovaries, pituitary, thymus, submaxillary glands and thyroid glands and the esophagus, stomach, small and large intestine, pancreas, ischiatic nerve, urinary bladder, seminal vesicles, uterus, prostate and, mysenteric lymph nodes as well as samples of spinal cord, skeletal muscle and bone marrow were fixed in 10% buffered formalin solution for routine histological processing. Paraffin sections were stained with hematoxylin and eosin for histopatbological examination. - Statistics:
- All quantitative data, except for the histopathological findings were statistically analyzed by one-way analysis of variance (ANOVA) techniques with Dunnett's or Scheff ’s multiple comparison procedures. Significance was established at the p<0.05 level.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
- Details on results:
- Clinical signs and mortality:
Mortlaity: No mortality was noted in male and female rats
Clinical signs: No signs of toxicity were observed in the tested animals
Body weight and weight gain: Decrease in body weight gain was observed. The rats of both sexes receiving 50 mg/kg showed emaciation and severe suppression in body weight gain one week after treatment started. No significant differences in body weight gain were observed in the groups that received 10 mg/kg 2-MBI or less.
Food consumption and compound intake: Decreased food consumption one week after treatment started was observed.
Food efficiency: No data
Water consumption and compound intake: No data
Opthalmoscopic examination: No data
Haematology: At the termination of the treatment, significant decreases in WBC in the 10 and 50 mg/kg female rats were observed. At the end of the recovery period, RBC, Hb and HCT were significantly decreased in both the male and female 50 mg/kg groups showing delayed onset of anemia. Increased active partial thromboplastin time was observed for both the males and females receiving 50 mg/kg.
Clinical chemistry: Serum levels of TP, BUN, PL, T-CHO, F-CHO,CHE and ɣ -GTP were significantly increased in both males and females given 50 mg/kg. ALP,K+ and Pi were decreased significantly in male rats receiving more than 10 mg/kg , and Na+ was increased significantly in the 50 mg/kg trated animals. CHO and PL levels remained significantly high 2 weeks after termination.
Urinanalysis: No data
Neurobehaviour: No data
Organ weights: Dose related inncreases in absolute and relative weights of thyroid, liver and kidney were observed. At 10 mg/kg, the mean absolute and relative thyroid weights in both sexes were approximately 3 times those of the control rats and in the 50mg/kg dose group the increase in relative thyroid weight was more than 10-fold. Dose related decreases in absolute and relative thymus weights in all the treatment groups of male and female rats and a derease in relative spleen weight in both males and females receiving 50 mg/kg were also observed. Significant increases in brain, lung, adrenal and pituitary gland weights and decreases in heart and sabmaxilIary gland and of relative organ weights were also observed with 50 mg/kg. Reduction in thymus weight was also observed in a dose-dependent manner without significant histopathological alteration.
Gross pathology: Marked enlargement of thyroid glands and thymus involution were evident. Diffuse hyperplasia of tall and columnar epithelial cells of follicles, and decrease in colloid and thickening of fibrous capsule appeared.
Histopathology:Hypertrophic cells in the anterior pituitary glands were found, Calcification of the collecting tubules in kidneay and fatty changes in adrenal cortex was observed
Effect levels
- Dose descriptor:
- NOEL
- Effect level:
- < 2 other: mg/kg/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: based on the significant decrease in thymus weight in the 2 mg/kg 2-MBI treatment group.
- Remarks on result:
- other: No toxic effects were observed
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Table: Hematological findings for rats after 28 days and 2 week recovery period
Group |
Treatment |
Recovery |
||||
No. of animals |
Control 5 |
2 mg/Kg 5 |
10 mg/Kg 5 |
50 mg/Kg 5 |
Control 5 |
50 mg/Kg 5 |
Male |
|
|
|
|
|
|
RBC |
9.00±0.10 |
9.07±0.37 |
8.60±0.19 |
8.66±0.25 |
9.86±0.19 |
7.49±0.13** |
Hb |
15.8±0.4 |
15.9±0.4 |
15.4±0.4 |
15.7±0.4 |
16.3±0.3 |
13.7±0.2** |
HCT |
47.1±0.4 |
46.7±1.6 |
45.8±1.6 |
44.0±1.5** |
48.0±0.6 |
39.8±0.9** |
PLT |
0.81±0.08 |
0. 84±0.09 |
0.79±0.18 |
0.63±0.05** |
0.84±0.13 |
1.06±0.08* |
WBC |
7.36±0.83 |
6.66±0.36 |
6.58±0.35 |
6.46±0.83 |
8.22±0.68 |
6.30±0.40 |
PT |
14.6±0.6 |
14.3±0.8 |
14.8±0.8 |
14.9±0.9 |
16.3±0.5 |
15.2±0.3** |
APTT |
24.7±2.1 |
24.2±4.1 |
25.6±2.7 |
35.6 v0.8* |
30.0±6.7 |
25.2±2.6 |
Female |
|
|
|
|
|
|
RBC |
9.01±0.14 |
9.02±0.12 |
8.77±0.58 |
9.00±0.51 |
8.58±0.20 |
6.64±0.08 |
Hb |
16.2±0.2 |
16.2±0.3 |
15.9±1.0 |
16.3 v0.7 |
15.6±0.3 |
12.7 v0.5** |
HCT |
46.2±1.0 |
45.8±1.0 |
45.1±31 |
45.1±2.6 |
44.6±0.9 |
34.8± 0.6** |
PLT |
0.72±0.08 |
0.71±0.21 |
0.78±0.16 |
0.67±0.15 |
1.04±0.06 |
1.22±0.08** |
WBC |
8.78±1.05 |
7.62±1.33 |
5.98±1.06** |
5.24±0.31** |
5.84±0.65 |
6.24±1.2 |
*, **: Significantly different from the relevant control at p<0.05, p<0.01, respectively
Table no 2: Biochemical findings for male rats after 28 days of treatment with test substance & 2-week recovery Period
Groups |
Treatment |
Recovery |
||||
|
control |
2mg/Kg |
10 mg/Kg |
50 mg/Kg |
Control 5 |
50 mg/Kg |
TP |
5.98±0.16 |
6.01 ±0.15 |
6.20 ±0.22 |
6.99 ±0.08 |
6.32 ±0.16 |
5.79 ±0.10 |
ALB |
4.25 ±0.07 |
4.24 ±0.12 |
4.33± 0.10 |
4.86 ±0.06 |
4.38 ±0.05 |
3.94 ±0.09 |
BUN |
8.89±1.26 |
8.09±0.89 |
6.65±0.31 |
12.77±0.49 |
12.1±1.40 |
11.1±0.4 |
CRN |
0.28±0.03 |
0.27±0.04 |
0.24±0.02 |
0.28±0.02 |
0.34±0.07 |
0.24±0.02 |
GLC |
118±4 |
120±13 |
124±6 |
124±6 |
130±7 |
108±8 |
PL |
103±3 |
108± 9 |
107± 9 |
226± 16 |
121± 5 |
160± 12 |
TG |
76± 15 |
82 ±14 |
74 ±23 |
65 ±10 |
157± 23 |
85± 12 |
T-CHO |
52± 4 |
54± 6 |
65± 7 |
180 ±11 |
59± 2 |
105 ±11 |
F-CHO |
7.6± 1.6 |
7.1± 2.3 |
10.0 ±1.7 |
46.4± 3.5 |
11.4 ±1.6 |
23.1 ±3.7 |
ALP |
323± 29 |
312 ±9 |
206 ±24 |
187± 26 |
198± 11 |
262 ±28 |
AST |
82± 8 |
81± 4 |
69± 8 |
54± 3 |
62± 16 |
64± 6 |
CHE |
174 ±15 |
186± 21 |
536 ±53 |
2013± 289 |
173 ±32 |
480± 42 |
-GTP |
1.29± 0.40 |
1.33 ±0.22 |
1.42 ±0.37 |
1.98 ±0.09 |
0.01± 0 |
0.01± 0 |
LAP |
47± 2 |
45± 1 |
47± 2 |
65± 4 |
42± 2 |
48± 2 |
Ca |
9.9± 0.1 |
9.9± 0.2 |
9.9 ±0.2 |
9.8± 0.3 |
10.5± 0.1 |
10.2± 0.2 |
Pi |
7.9 ±0.3 |
7.7 ±0.3 |
7.1± 0.3 |
5.4± 0.2 |
7.3± 0.3 |
7.6± 0.3 |
Na |
137± 1 |
137± 1 |
138 ±1 |
142 ±1 |
136± 1 |
136± 1 |
K |
5.2± 0.2 |
4.9± 0.3 |
4.7± 0.2 |
3.5 ±0.1 |
4.3± 0.3 |
5.0± 0.2 |
Cl |
100± 0 |
99± 1 |
98 ±2 |
98± 1 |
99± 1 |
103± 1 |
Table no : Biochemical findings for female rats after 28 days of treatment with test substance & 2-week recovery Period
Groups |
Treatment |
Recovery |
||||
|
control |
2mg/Kg |
10 mg/Kg |
50 mg/Kg |
Control 5 |
50 mg/Kg |
TP |
5.92 0.16 |
5.81 0.15 |
5.88 0.06 |
6.70 0.23 |
6.29 0.23 |
6.31 1.05 |
ALP |
4.30± 0.12 |
4.29± 0.10 |
4.29± 0.05 |
4.60± 0.14 |
4.44± 0.19 |
3.78± 0.08 |
A/G |
2.67± 0.18 |
2.83± 0.11 |
2.71± 0.10 |
2.19± 0.13 |
2.41± 0.15 |
1.66± 0.5 |
CRN |
0.29 ±0.04 |
0.29 ±0.04 |
0.27± 0.03 |
0.41 ±0.07 |
0.32± 0.01 |
0.30± 0.02 |
PL |
154 ±8 |
139 ±9 |
123± 7 |
265 ±22 |
173± 14 |
187 ±14 |
TG |
52± 2 |
49± 12 |
41± 4 |
65 ±12 |
55± 11 |
64 ±15 |
T-CHO |
85± 7 |
74± 5 |
73± 6 |
208 ±22 |
95± 4 |
121± 13 |
F-CHO |
19.0± 2.0 |
15.8± 1.4 |
15.2± 1.7 |
59.1± 4.0 |
23.3± 1.5 |
30.0± 3.1 |
ALP |
200± 29 |
200± 28 |
138± 7 |
183± 51 |
131± 12 |
153± 18 |
AST |
74± 7 |
75± 6 |
68± 4 |
62± 4 |
63± 4 |
61± 5 |
CHE |
1230 ±235 |
1350± 146 |
1380± 152 |
2096± 41 |
1566± 293 |
1421± 147 |
-GTP |
0.70 ±0.18 |
0.57± 0.21 |
0.69± 0.24 |
1.25± 0.31 |
0.03 ±0.02 |
0.10± 0.21 |
LAP |
46± 3 |
44 1 |
45 1 |
68 3 |
43 3 |
48 3 |
Pi |
6.4 0.3 |
6.1± 0.2 |
6.1± 0.3 |
5.5± 0.2 |
5.1± 0.3 |
6.8 ±0.3 |
Na |
138± 0 |
138± 1 |
140± 1 |
143± 2 |
137± 0 |
135± 1 |
K |
4.5± 0.2 |
4.4± 0.2 |
3.9± 0.1 |
3.1± 0.1 |
4.4± 0.2 |
4.6 ±0.1 |
Applicant's summary and conclusion
- Conclusions:
- The no-observed adverse effect level (NOAEL) of test substance in oral gavage study was considered to be less than 2 mg/kg/day based on the significant decrease in thymus weight in the 2 mg/kg test substance treatment group.
- Executive summary:
In order to determine the oral toxicity of test substance, a 28-day repeated dose toxicity study in Wistar rats followed by observation over a 14-day recovery period was conducted at dose levels of 0, 2, 10 and 50 mg/kg administered by gavage. No toxic deaths occurred due to test substance treatment. Decreases of body weight gain and food consumption in the 50 mg/kg dose group were observed during the second half of the treatment period. In addition, hematological examination and serum biochemical tests revealed decreased white blood cells and hemoglobin and increased serum urea nitrogen, cholesterol, phospholipid, ɣ-glutamyl transpeptidase and the Na+/K+ ratio in the 50 mg/kg dose group. Marked thyroid enlargement (to 10 fold the control weight), histopathologically associated with diffuse hyperplasia of follicles with decreased colloid and thickening of the fibrous capsule, was found. Reduction in thymus weight was also observed in a dose-dependent manner without significant histopathological alteration. The no-observed adverse effect level (NOAEL) of test substance in oral gavage study was found to be less than 2 mg/kg/day based on the significant decrease in thymus weight in the 2 mg/kg test substance treatment group.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.